FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200370209> ?p ?o ?g. }

• W4200370209 endingPage "e003441" @default.
• W4200370209 startingPage "e003441" @default.
• W4200370209 abstract "Glypican-3 (GPC-3) is an oncofetal protein that is highly expressed in various solid tumors, but rarely expressed in healthy adult tissues and represents a rational target of particular relevance in hepatocellular carcinoma (HCC). Autologous chimeric antigen receptor (CAR) αβ T cell therapies have established significant clinical benefit in hematologic malignancies, although efficacy in solid tumors has been limited due to several challenges including T cell homing, target antigen heterogeneity, and immunosuppressive tumor microenvironments. Gamma delta (γδ) T cells are highly cytolytic effectors that can recognize and kill tumor cells through major histocompatibility complex (MHC)-independent antigens upregulated under stress. The Vδ1 subset is preferentially localized in peripheral tissue and engineering with CARs to further enhance intrinsic antitumor activity represents an attractive approach to overcome challenges for conventional T cell therapies in solid tumors. Allogeneic Vδ1 CAR T cell therapy may also overcome other hurdles faced by allogeneic αβ T cell therapy, including graft-versus-host disease (GvHD).We developed the first example of allogeneic CAR Vδ1 T cells that have been expanded from peripheral blood mononuclear cells (PBMCs) and genetically modified to express a 4-1BB/CD3z CAR against GPC-3. The CAR construct (GPC-3.CAR/secreted interleukin-15 (sIL)-15) additionally encodes a constitutively-secreted form of IL-15, which we hypothesized could sustain proliferation and antitumor activity of intratumoral Vδ1 T cells expressing GPC-3.CAR.GPC-3.CAR/sIL-15 Vδ1 T cells expanded from PBMCs on average 20,000-fold and routinely reached >80% purity. Expanded Vδ1 T cells showed a primarily naïve-like memory phenotype with limited exhaustion marker expression and displayed robust in vitro proliferation, cytokine production, and cytotoxic activity against HCC cell lines expressing low (PLC/PRF/5) and high (HepG2) GPC-3 levels. In a subcutaneous HepG2 mouse model in immunodeficient NSG mice, GPC-3.CAR/sIL-15 Vδ1 T cells primarily accumulated and proliferated in the tumor, and a single dose efficiently controlled tumor growth without evidence of xenogeneic GvHD. Importantly, compared with GPC-3.CAR Vδ1 T cells lacking sIL-15, GPC-3.CAR/sIL-15 Vδ1 T cells displayed greater proliferation and resulted in enhanced therapeutic activity.Expanded Vδ1 T cells engineered with a GPC-3 CAR and sIL-15 represent a promising platform warranting further clinical evaluation as an off-the-shelf treatment of HCC and potentially other GPC-3-expressing solid tumors." @default.
• W4200370209 created "2021-12-31" @default.
• W4200370209 creator A5000588690 @default.
• W4200370209 creator A5003434490 @default.
• W4200370209 creator A5005105589 @default.
• W4200370209 creator A5020742853 @default.
• W4200370209 creator A5021285576 @default.
• W4200370209 creator A5023369824 @default.
• W4200370209 creator A5047300161 @default.
• W4200370209 creator A5058180593 @default.
• W4200370209 creator A5059572232 @default.
• W4200370209 creator A5064652611 @default.
• W4200370209 creator A5065983782 @default.
• W4200370209 creator A5071025112 @default.
• W4200370209 creator A5077148194 @default.
• W4200370209 creator A5081698122 @default.
• W4200370209 creator A5083400753 @default.
• W4200370209 creator A5085280649 @default.
• W4200370209 creator A5089958033 @default.
• W4200370209 date "2021-12-01" @default.
• W4200370209 modified "2023-10-12" @default.
• W4200370209 title "Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma" @default.
• W4200370209 cites W1107917109 @default.
• W4200370209 cites W1910012553 @default.
• W4200370209 cites W1995930566 @default.
• W4200370209 cites W2003197307 @default.
• W4200370209 cites W2017288179 @default.
• W4200370209 cites W2048879854 @default.
• W4200370209 cites W2053286465 @default.
• W4200370209 cites W2053643795 @default.
• W4200370209 cites W2062719961 @default.
• W4200370209 cites W2117850100 @default.
• W4200370209 cites W2136713170 @default.
• W4200370209 cites W2219506342 @default.
• W4200370209 cites W2341498785 @default.
• W4200370209 cites W2402532535 @default.
• W4200370209 cites W2409483347 @default.
• W4200370209 cites W2525994542 @default.
• W4200370209 cites W2602369513 @default.
• W4200370209 cites W2626153771 @default.
• W4200370209 cites W2738977754 @default.
• W4200370209 cites W2801641802 @default.
• W4200370209 cites W2803500691 @default.
• W4200370209 cites W2807103182 @default.
• W4200370209 cites W2807110328 @default.
• W4200370209 cites W2888063816 @default.
• W4200370209 cites W2891496270 @default.
• W4200370209 cites W2891641168 @default.
• W4200370209 cites W2898416763 @default.
• W4200370209 cites W2907689723 @default.
• W4200370209 cites W2913136103 @default.
• W4200370209 cites W2928871599 @default.
• W4200370209 cites W2936042979 @default.
• W4200370209 cites W2947301297 @default.
• W4200370209 cites W2947851642 @default.
• W4200370209 cites W2948007475 @default.
• W4200370209 cites W2968960744 @default.
• W4200370209 cites W2971477701 @default.
• W4200370209 cites W2972280750 @default.
• W4200370209 cites W2980303761 @default.
• W4200370209 cites W2986929420 @default.
• W4200370209 cites W2999031113 @default.
• W4200370209 cites W3004611567 @default.
• W4200370209 cites W3006578254 @default.
• W4200370209 cites W3008406481 @default.
• W4200370209 cites W3015471245 @default.
• W4200370209 cites W3023954831 @default.
• W4200370209 cites W3044843687 @default.
• W4200370209 cites W3093388579 @default.
• W4200370209 cites W3097007136 @default.
• W4200370209 cites W3142222967 @default.
• W4200370209 doi "https://doi.org/10.1136/jitc-2021-003441" @default.
• W4200370209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34916256" @default.
• W4200370209 hasPublicationYear "2021" @default.
• W4200370209 type Work @default.
• W4200370209 citedByCount "55" @default.
• W4200370209 countsByYear W42003702092022 @default.
• W4200370209 countsByYear W42003702092023 @default.
• W4200370209 crossrefType "journal-article" @default.
• W4200370209 hasAuthorship W4200370209A5000588690 @default.
• W4200370209 hasAuthorship W4200370209A5003434490 @default.
• W4200370209 hasAuthorship W4200370209A5005105589 @default.
• W4200370209 hasAuthorship W4200370209A5020742853 @default.
• W4200370209 hasAuthorship W4200370209A5021285576 @default.
• W4200370209 hasAuthorship W4200370209A5023369824 @default.
• W4200370209 hasAuthorship W4200370209A5047300161 @default.
• W4200370209 hasAuthorship W4200370209A5058180593 @default.
• W4200370209 hasAuthorship W4200370209A5059572232 @default.
• W4200370209 hasAuthorship W4200370209A5064652611 @default.
• W4200370209 hasAuthorship W4200370209A5065983782 @default.
• W4200370209 hasAuthorship W4200370209A5071025112 @default.
• W4200370209 hasAuthorship W4200370209A5077148194 @default.
• W4200370209 hasAuthorship W4200370209A5081698122 @default.
• W4200370209 hasAuthorship W4200370209A5083400753 @default.
• W4200370209 hasAuthorship W4200370209A5085280649 @default.
• W4200370209 hasAuthorship W4200370209A5089958033 @default.
• W4200370209 hasBestOaLocation W42003702091 @default.
• W4200370209 hasConcept C10882517 @default.

• next